MedTrace Logo

Cross-cultural Adaptation of the Safety Assessment Scale for Elderly People With a Major Neurocognitive Disorder Living at Home.

NCT05485090 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2025-11-17

No results posted yet for this study

Summary

The main objective of this study is to adapt the Canadian French version of the safety assessment scale for use in France. The Safety Assessment Scale was developped for community healthcare providers working with elderly people with dementia who are being cared for at home, to assess the risk of accidents. The short version of the Safety Assessment Scale is a screening tool and the longer version provides an in-depth evaluation of safety.

This scale is a risk assessment grid for accidents and injuries at home for elderly people with major neurocognitive disorders, available in English and French (Canadian). There are two versions:

* The short version is used for screening. A score of 11 to 14 indicates a moderate risk of injury, while a score ≥ 15 indicates a high risk of injury;
* The long version is used for in-depth assessment when the score on the short version indicates a moderate or high risk of injury. The questionnaire is divided into nine sections:

1. Caregiver and environment, 2/smoking, 3/fire and burns, 4/nutrition, 5/food poisoning and toxic substances, 6/medication and health problems, 7/wandering and adaptation to temperature changes, 8/trauma, and 9/driving.

The short version includes some of the questions from sections 1 to 7 of the long version.

Conditions

  • Major Neurocognitive Disorder

Interventions

OTHER

Questionnaire : Adapted Safety Assessment Scale

Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.

Sponsors & Collaborators

  • Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

    lead OTHER

Principal Investigators

  • Clémence BONNOT, Occupational Therapist · Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-12-08
Completion
2023-12-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05485090 on ClinicalTrials.gov